Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Change in Receivables (2018 - 2025)

TransMedics has reported Change in Receivables over the past 8 years, most recently at $3.6 million for Q4 2025.

  • Quarterly results put Change in Receivables at $3.6 million for Q4 2025, down 54.32% from a year ago — trailing twelve months through Dec 2025 was -$14.0 million (down 140.66% YoY), and the annual figure for FY2025 was -$14.0 million, down 140.66%.
  • Change in Receivables for Q4 2025 was $3.6 million at TransMedics, up from -$24.1 million in the prior quarter.
  • Over the last five years, Change in Receivables for TMDX hit a ceiling of $44.1 million in Q1 2025 and a floor of -$37.5 million in Q2 2025.
  • Median Change in Receivables over the past 5 years was $4.5 million (2022), compared with a mean of $3.8 million.
  • Biggest five-year swings in Change in Receivables: soared 895.54% in 2022 and later plummeted 4856.14% in 2025.
  • TransMedics' Change in Receivables stood at $1.8 million in 2021, then skyrocketed by 197.85% to $5.4 million in 2022, then crashed by 47.71% to $2.8 million in 2023, then soared by 178.15% to $7.8 million in 2024, then crashed by 54.32% to $3.6 million in 2025.
  • The last three reported values for Change in Receivables were $3.6 million (Q4 2025), -$24.1 million (Q3 2025), and -$37.5 million (Q2 2025) per Business Quant data.